Equity Rights Offering
Company: Core Scientific
The claim, verbatim
The company commenced an equity rights offering of common shares of the reorganized company in an aggregate amount of $55 million, which was oversubscribed
Source (primary)
Core Scientific 8-K filed 2024-01-08 (SEC EDGAR, sec_filing)
View cached copy (2026-08-31)Live source ↗
Quote: “on November 20, 2023, the Company commenced an equity rights offering (the " Equity Rights Offering ") of common shares of the reorganized Company (the " ERO Shares ") in an aggregate amount of $55 million”
How we checked this
Checked on September 18, 2026. The cited source supports every part of this claim.
The filing states Core Scientific commenced a $55 million equity rights offering of reorganized-company common shares on November 20, 2023, and that the offering was oversubscribed, making the backstop unnecessary.
Confirmed in the source:
- The company commenced an equity rights offering of common shares of the reorganized company
- The equity rights offering was in an aggregate amount of $55 million
- The equity rights offering was oversubscribed
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/1839341/000119312524004018/d109221d8k.htm) in full (13,364 characters, retrieved August 31, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific 8-K filed 2024-01-08
Quote: “on November 20, 2023, the Company commenced an equity rights offering (the " Equity Rights Offering ") of common shares of the reorganized Company (the " ERO Shares ") in an aggregate amount of $55 million”